Novo Nordisk (CPSE:NOVO B) is back in focus after the FDA cleared its high dose Wegovy HD in the US, while patent protection for semaglutide in India expires, opening the door to lower cost rivals.<\/p>\n
See our latest analysis for Novo Nordisk.<\/a><\/p>\n The FDA approval for Wegovy HD arrives at a time when short term sentiment has cooled, with a 30 day share price return of 23.72% and a 1 year total shareholder return decline of 53.81%, suggesting recent momentum has faded despite longer term gains over 5 years.<\/p>\n If this kind of obesity and diabetes story has your attention, it can be useful to compare with other health focused names using a dedicated screener such as 127 healthcare AI stocks<\/a><\/p>\n With Novo Nordisk shares showing negative returns over 1 and 3 years despite a 5 year gain, and tools suggesting the stock trades at a discount to some estimates of intrinsic value, is this recent weakness a buying opportunity, or is the market already pricing in future growth?<\/p>\n Most Popular Narrative: 72.1% Undervalued <\/p>\n Tokyo\u2019s widely followed narrative pegs Novo Nordisk\u2019s fair value at DKK851.04 per share, versus a last close of DKK237.45, indicating a very wide valuation gap.<\/p>\n With high barriers to entry, a booming market for obesity treatment, and a pipeline that keeps expanding, Novo Nordisk\u2019s future looks remarkably secure. The company also benefits from deep expertise, a strong brand, and a massive manufacturing network that rivals would struggle to replicate.<\/p>\n Read the complete narrative.<\/a><\/p>\n Curious what justifies such a big gap between price and fair value? The narrative refers to robust revenue expansion, strong margins and a confident future earnings multiple. The exact mix of these inputs may surprise you.<\/p>\n Result: Fair Value of DKK851.04 (UNDERVALUED)<\/p>\n Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n However, investors still need to watch for pricing pressure if lower cost semaglutide rivals scale up, and for any regulatory shifts around obesity and diabetes treatments.<\/p>\n Find out about the key risks to this Novo Nordisk narrative.<\/a><\/p>\n Next Steps <\/p>\n Given the mix of concern and optimism in this story, it makes sense to move quickly and test the numbers yourself using the 4 key rewards and 5 important warning signs<\/a>.<\/p>\n Looking for more investment ideas? <\/p>\n If Novo Nordisk has sharpened your curiosity, do not stop here. Widen your watchlist with fresh ideas that could suit very different investing goals.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data Valuation is complex, but we’re here to simplify it.<\/p>\n Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.<\/p>\n Access Free Analysis<\/a><\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (CPSE:NOVO B) is back in focus after the FDA cleared its high dose Wegovy HD in…\n","protected":false},"author":2,"featured_media":360847,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[103,61,60,371],"class_list":["post-360846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-ie","tag-ireland","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/360846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=360846"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/360846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/360847"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=360846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=360846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=360846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
\n financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
\n Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
\n Simply Wall St has no position in any stocks mentioned.<\/p>\n